- Founder, CEO of Oncolinx
- Strategy at Celularity
- Forbes’ “30 Under 30: Healthcare”
- World Economic Forum Global Shaper
- Singularity University Global Solutions Program
- Dartmouth College
-
Sourav Sinha
Partner & Head of Strategy
Sourav Sinha
-
Kris Verburgh, MD
Partner & Head of Science
Kris Verburgh, MD
- Medical doctor, specializing in health, aging and the future of medicine and biotechnology
- Researcher at Free University of Brussels
- Faculty member Singularity University Benelux (Medicine and Longevity)
- Creator of nutrigerontology, a new scientific discipline studying the impact of nutrition on the aging process and age-related diseases
- Author of “The Longevity Code”
-
Dmitry Vorontsov
Director, Finance & Investments
Dmitry Vorontsov
- Finance professional with 15+ years’ experience in all aspects of corporate finance and accounting
- Has work experience at large US financial and investment companies – Dynasty Financial Partners, Jamison Capital and The Carlyle Group hedge funds, as well as Barclays and Renaissance Capital investment banks
- Master’s degree in Accounting, Financial Analysis and Audit
-
Tim Safin
Associate
Tim Safin
- Investment professional with a primary focus on biotechnology venture capital
- Experienced in VC and public companies investments focusing on the development of breakthrough therapies
- Previously worked in Strategy Consulting (IQVIA and KPMG) supporting Big Pharma and Biotechnology companies in organic business growth, M&A and transformation
-
Gunner Hardy
Analyst
Gunner Hardy
- Investment professional with a primary focus on biotechnology venture capital
- Experienced in banking and private company investments covering origination, structuring, execution, and implementation
- Previously worked in Banking (BAML, EBRD and World Bank) and Life Sciences Research (Skoltech)
- Master’s degrees in Life Sciences (Biotechnology) and Finance
-
Sun Altbach
Senior Scientific Advisor
Sun Altbach
- Biopharmaceutical executive and entrepreneur with 20 years of experience
- Have advanced innovative therapies through key inflection points for private, early-stage companies as well as some of the industry’s preeminent publicly listed global firms
- Previously worked at Biogen, Sanofi Genzyme, Shire Pharmaceuticals
- Founding CEO of PIC Therapeutics, cancer therapeutics company
- Advisory Board Member at The Termeer Foundation
- Member of Women In Bio association